Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Am J Ophthalmol. 2021 Sep;229:90-99. doi: 10.1016/j.ajo.2021.04.003. Epub 2021 Apr 20.
Reporting treatment outcomes of slow coagulation transscleral cyclophotocoagulation (TSCPC) as an initial surgical intervention in pseudophakic patients with glaucoma.
Retrospective case series.
This single academic center study reviewed 74 pseudophakic patients who had a diagnosis of glaucoma and no previous glaucoma surgeries (mean age 82.6 ± 12.5 years; mean follow-up 18.7 ± 9.1 months). The intervention used was slow coagulation continuous wave TSCPC (1250-mW power and 4-second duration). The primary outcome measure was surgical success defined as an intraocular pressure (IOP) of 6-21 mm Hg with a ≥20% reduction from baseline, no reoperation for glaucoma, and no loss of light-perception vision. Secondary outcome measures included glaucoma medication use, visual acuity (VA), and complications.
IOP decreased from 27.5 ± 9.8 mm Hg preoperatively to 16.1 ± 6.3 mm Hg postoperatively (P < .001). The preoperative number of glaucoma medications was 4.1 ± 0.9 and 3.1 ± 1.3 post-TSCPC (P < .001). The cumulative probabilities of success at 1 and 2 years were 60.6 % and 58.5%, respectively. When patients were divided into 2 groups based on their baseline IOP being >21 mm Hg (high group) or ≤21 mm Hg (low group), success rates at 2 years were 64.9% and 45.5%, respectively (P = .144). The mean logarithm of the minimum angle of resolution VA changed from 0.70 ± 0.64 to 1.04 ± 0.87 at the last follow-up visit (P = .01). No serious complications were observed and most of the complications were mild and transient.
Slow coagulation TSCPC has good efficiency, especially in patients with baseline IOP >21 mm Hg, and safety profile as an initial surgical intervention in pseudophakic patients with glaucoma.
报告以缓慢凝血模式行巩膜透热光凝术(TSCPC)作为治疗白内障术后青光眼患者的初始手术干预的治疗结果。
回顾性病例系列研究。
这项单中心研究回顾了 74 名被诊断为青光眼且无既往青光眼手术史的白内障术后患者(平均年龄 82.6 ± 12.5 岁;平均随访 18.7 ± 9.1 个月)。采用缓慢凝血连续波 TSCPC(功率 1250 mW,持续时间 4 秒)进行干预。主要观察指标为手术成功,定义为眼压(IOP)为 6-21mmHg,较基线值降低≥20%,无需再次行青光眼手术,且无光感丧失。次要观察指标包括青光眼药物使用、视力(VA)和并发症。
IOP 从术前的 27.5 ± 9.8mmHg 降至术后的 16.1 ± 6.3mmHg(P<.001)。术前青光眼药物的使用数量为 4.1 ± 0.9 种,术后为 3.1 ± 1.3 种(P<.001)。术后 1 年和 2 年的累积成功率分别为 60.6%和 58.5%。根据基线 IOP>21mmHg(高眼压组)或≤21mmHg(低眼压组)将患者分为 2 组,术后 2 年的成功率分别为 64.9%和 45.5%(P=.144)。最后一次随访时,最小分辨角对数视力(VA)均值从 0.70 ± 0.64 变为 1.04 ± 0.87(P=.01)。未观察到严重并发症,大多数并发症为轻度且短暂。
作为白内障术后青光眼患者的初始手术干预,缓慢凝血 TSCPC 具有良好的疗效,尤其是在基线 IOP>21mmHg 的患者中,且具有良好的安全性。